Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine
Fig 7
Tumor diameter when optimizing J1 and J2, and optimal (blue and green curves), suboptimal (dotted, solid, and dashed orange are 3, 1, and 0.1 folds of clinical trial dose, respectively) and no (red) vaccinations are applied. Numbers with an arrow are pointing at the blue curve when t = 200 days, represent the tumor diameter at the end of the treatment (from J1). The vertical green dashed lines correspond to the days of vaccination.